^
Association details:
| Biomarker: | FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + idarubicin (DNA replication inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial
Published date:
11/01/2018
Excerpt:
...study has explored the role of mutation patterns determined by NGS in older AML pts...Pts received one 7+3 course followed by 2 intermediate-dose cytarabine courses…In a multivariate analysis accounting for clinical covariates...FLT3-ITDhigh (HR=2.00, p=0.03), mutations in DNMT3A (HR=1.74, p=0.001), ASXL1 (HR=1.84, p=0.002) and NRAS (HR=1.70, p=0.009), but not RUNX1 or TP53, independently predicted worse OS...
DOI:
10.1182/blood-2018-99-111144
Trial ID:
